Literature DB >> 17022761

Fluconazole and itraconazole susceptibilities of Candida spp. isolated from oropharyngeal specimens and blood cultures of paediatric haematology/oncology patients.

H F Kennedy1, G S Shankland, J Bagg, E A Chalmers, B E S Gibson, C L Williams.   

Abstract

This study examined the in vitro susceptibilities to fluconazole and itraconazole of isolates of Candida spp. from surveillance oropharyngeal specimens and blood cultures from paediatric patients with malignancy. The species distribution of 100 isolates from oropharyngeal specimens was C. albicans 86%, C. glabrata 7%, C. lusitaniae 4%, C. parapsilosis 2% and C. tropicalis 1%. From a total of nine isolates from blood cultures the species distribution was C. albicans 33.3%, C. parapsilosis 33.3 % and C. guilliermondii 33.3%. Only three of the oropharyngeal isolates were resistant to fluconazole (MIC > or = 64 mg l(-1)) and only two were resistant to itraconazole (MIC > or = 1 mg l(-1)). None of the blood culture isolates was resistant to either agent. At this centre, C. albicans is the predominant species from oropharyngeal specimens, but non-albicans Candida species predominate in blood cultures. Although resistance to fluconazole and itraconazole is rare at present, continued surveillance is warranted to monitor trends in species distribution and antifungal susceptibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17022761     DOI: 10.1111/j.1439-0507.2006.01272.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  1 in total

1.  Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates.

Authors:  Janine de Aquino Lemos; Carolina Rodrigues Costa; Crystiane Rodrigues de Araújo; Lúcia Kioko Hasimoto E Souza; Maria do Rosário Rodrigues Silva
Journal:  Braz J Microbiol       Date:  2009-03-01       Impact factor: 2.476

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.